SeaBridge Investment Advisors LLC Lowers Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

SeaBridge Investment Advisors LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,571 shares of the medical research company’s stock after selling 511 shares during the period. Thermo Fisher Scientific makes up about 1.2% of SeaBridge Investment Advisors LLC’s holdings, making the stock its 24th biggest position. SeaBridge Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $5,499,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Quarry LP boosted its holdings in Thermo Fisher Scientific by 86.2% during the second quarter. Quarry LP now owns 121 shares of the medical research company’s stock worth $67,000 after buying an additional 56 shares in the last quarter. Mattson Financial Services LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $1,078,000. AMF Tjanstepension AB purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $42,409,000. Czech National Bank boosted its stake in shares of Thermo Fisher Scientific by 7.0% during the 3rd quarter. Czech National Bank now owns 77,816 shares of the medical research company’s stock worth $48,135,000 after acquiring an additional 5,076 shares in the last quarter. Finally, Farmers Trust Co. boosted its stake in shares of Thermo Fisher Scientific by 70.9% during the 3rd quarter. Farmers Trust Co. now owns 622 shares of the medical research company’s stock worth $385,000 after acquiring an additional 258 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 1.4 %

TMO stock opened at $598.40 on Friday. The company has a market cap of $228.89 billion, a price-to-earnings ratio of 37.52, a PEG ratio of 3.89 and a beta of 0.76. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The business has a fifty day simple moving average of $541.37 and a 200-day simple moving average of $570.96. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific declared that its board has authorized a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now directly owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This represents a 38.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders sold 29,000 shares of company stock valued at $15,859,540. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TMO. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Wells Fargo & Company boosted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday. Citigroup upped their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research note on Friday. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, UBS Group upped their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $655.64.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.